| Dr William A Moore, MD | |
|
1 Mt Carmel Way, Pittsburg, KS 66762-7587 | |
| (620) 231-6100 | |
| Not Available |
| Full Name | Dr William A Moore |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 37 Years |
| Location | 1 Mt Carmel Way, Pittsburg, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134173800 | NPI | - | NPPES |
| 25865 | Medicaid | NM |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Los Alamos Physician Practices Llc | 4587661541 | 14 |
News Archive
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug.
RSB Spine, LLC, today announced that the InterPlate® C-Ti has been cleared for a new indication. When reclassification of interbody fusion devices occurred in 2007, the C-Ti was the first system cleared by the U.S. Food and Drug Administration. With this most recent announcement, the C-Ti has now become the first interbody fusion device to be cleared as an anterior cervical plate as well.
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
› Verified 5 days ago
| Entity Name | Presbyterian Healthcare Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104802354 PECOS PAC ID: 9234041708 Enrollment ID: O20031103000603 |
News Archive
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug.
RSB Spine, LLC, today announced that the InterPlate® C-Ti has been cleared for a new indication. When reclassification of interbody fusion devices occurred in 2007, the C-Ti was the first system cleared by the U.S. Food and Drug Administration. With this most recent announcement, the C-Ti has now become the first interbody fusion device to be cleared as an anterior cervical plate as well.
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
› Verified 5 days ago
| Entity Name | Los Alamos Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750330510 PECOS PAC ID: 4587661541 Enrollment ID: O20061104000041 |
News Archive
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug.
RSB Spine, LLC, today announced that the InterPlate® C-Ti has been cleared for a new indication. When reclassification of interbody fusion devices occurred in 2007, the C-Ti was the first system cleared by the U.S. Food and Drug Administration. With this most recent announcement, the C-Ti has now become the first interbody fusion device to be cleared as an anterior cervical plate as well.
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William A Moore, MD 108 Wilmington Cir, Clovis, NM 88101-9311 Ph: (575) 749-1739 | Dr William A Moore, MD 1 Mt Carmel Way, Pittsburg, KS 66762-7587 Ph: (620) 231-6100 |
News Archive
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug.
RSB Spine, LLC, today announced that the InterPlate® C-Ti has been cleared for a new indication. When reclassification of interbody fusion devices occurred in 2007, the C-Ti was the first system cleared by the U.S. Food and Drug Administration. With this most recent announcement, the C-Ti has now become the first interbody fusion device to be cleared as an anterior cervical plate as well.
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
› Verified 5 days ago
Victoria A. Shirley, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Centennial Dr, Pittsburg, KS 66762 Phone: 620-230-0044 Fax: 620-230-0543 | |
Gary A. Grimaldi, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2701 S. Rouse, Ste. A, Pittsburg, KS 66762 Phone: 620-235-7605 Fax: 620-231-0081 | |
Dr. Michael Sean Fenech, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Centennial Dr, Pittsburg, KS 66762 Phone: 620-230-0044 Fax: 620-230-0543 | |
Dennis G. Higginbotham, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Mt Carmel Way, Pittsburg, KS 66762 Phone: 620-230-0044 Fax: 620-230-0543 | |
Angela C Shaw, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Centennial Dr, Pittsburg, KS 66762 Phone: 620-230-0044 Fax: 620-230-0543 | |
Kari Elizabeth Hamlin, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Centennial Dr, Pittsburg, KS 66762 Phone: 620-230-0044 |